<?xml version='1.0' encoding='utf-8'?>
<document id="16621244"><sentence text="Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1."><entity charOffset="0-13" id="DDI-PubMed.16621244.s1.e0" text="Schisandrin B" /></sentence><sentence text="We recently reported that schisandrin B (Sch B) was a novel P-glycoprotein (P-gp) inhibitor"><entity charOffset="26-39" id="DDI-PubMed.16621244.s2.e0" text="schisandrin B" /></sentence><sentence text=" In this study, we revealed that Sch B was also an effective inhibitor of multidrug resistance-associated protein 1 (MRP1)" /><sentence text=" The activities of Sch B to reverse MRP1-mediated drug resistance was tested using HL60/ADR and HL60/MRP, the human promyelocytic leukemia cell lines with the overexpression of MRP1 but not P-gp" /><sentence text=" Sch B resumed daunorubicin and carboxyfluorescein diacetate (CFDA, a specific substrate for MRP1) accumulation and retention in HL60/ADR cells in a time and concentration dependent manner"><entity charOffset="15-27" id="DDI-PubMed.16621244.s5.e0" text="daunorubicin" /><entity charOffset="32-60" id="DDI-PubMed.16621244.s5.e1" text="carboxyfluorescein diacetate" /><entity charOffset="62-66" id="DDI-PubMed.16621244.s5.e2" text="CFDA" /><pair ddi="false" e1="DDI-PubMed.16621244.s5.e0" e2="DDI-PubMed.16621244.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16621244.s5.e0" e2="DDI-PubMed.16621244.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16621244.s5.e0" e2="DDI-PubMed.16621244.s5.e2" /><pair ddi="false" e1="DDI-PubMed.16621244.s5.e1" e2="DDI-PubMed.16621244.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16621244.s5.e1" e2="DDI-PubMed.16621244.s5.e2" /></sentence><sentence text=" At the equimolar concentration, Sch B demonstrated significantly stronger potency than probenecid, a MRP1 inhibitor"><entity charOffset="88-98" id="DDI-PubMed.16621244.s6.e0" text="probenecid" /></sentence><sentence text=" This study, together with the previous findings, demonstrated that Sch B was a dual inhibitor of P-gp and MRP1, a type suggested to be preferable to the use of combination of two specific modulators to prevent drug-drug interaction and cumulative toxicities" /><sentence text="" /></document>